Marine protein, particularly from sources like fish, fish collagen, and marine-derived peptides, has been investigated for its potential benefits in supporting bone health and managing osteoporosis. Scientific interest centers primarily on bioactive peptides and collagen extracted from marine sources, which may influence bone metabolism. Several animal studies and a growing number of small human clinical trials suggest that marine collagen peptides can enhance bone mineral density, stimulate osteoblast (bone-building cell) activity, and inhibit osteoclast (bone-resorbing cell) activity. The proposed mechanisms include improved calcium absorption, antioxidant effects, and stimulation of collagen synthesis in bone matrix.

For example, a 2017 review in Marine Drugs highlighted various marine peptides showing promise in preclinical osteoporosis models. Some small randomized controlled trials have reported improved markers of bone turnover and modest increases in bone mineral density in postmenopausal women supplementing with fish collagen or hydrolyzed marine protein. However, most human data are preliminary, with limited sample sizes, variable formulations, and short study durations. Notably, marine protein supplements are well tolerated, with few reported adverse effects.

In summary, there is moderate scientific support for the use of marine protein in osteoporosis, with encouraging preclinical results and emerging human evidence. However, larger, long-term clinical trials are needed to firmly establish efficacy and optimal dosing.